CAR T cell immunotherapy for human cancer

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509

Cancer regression in patients after transfer of genetically engineered lymphocytes

Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,564

Adoptive cell transfer as personalized immunotherapy for human cancer

Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,545

T cell exclusion, immune privilege, and the tumor microenvironment

Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,539

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

Kalos, M. D., Levine, B. L., Porter, D. L., Katz, S. I., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,417

CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities

Akhoundi, M., Mohammadi, M., Sahraei, S. S., Sheykhhasan, M., & Hosseini, N. F. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00593-1 · Cited by 68

Human Hyaluronidase PH20 Potentiates the Antitumor Activities of Mesothelin-Specific CAR-T Cells Against Gastric Cancer

Zhao, R., Cui, Y., Zheng, Y., Li, S., Lv, J., Wu, Q., Long, Y., Wang, S., Yao, Y., Wei, W., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.660488 · Cited by 66

CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy

Salas-McKee, J., Kong, W., Gladney, W. L., Jadlowsky, J. K., Plesa, G., Suhoski, M. M., & Fraietta, J. A. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1571893 · Cited by 68

Progress and challenges in HER2-positive gastroesophageal adenocarcinoma

Zhao, D., Klempner, S. J., & Chao, J. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0737-2 · Cited by 66

The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy

Liu, D., Badeti, S., Dotti, G., Jiang, J.-G., Wang, H., Dermody, J. J., Soteropoulos, P., Streck, D. L., Birge, R. B., & Liu, C. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00617-7 · Cited by 68

The distinct MHC‐unrestricted immunobiology of innate‐like and adaptive‐like human γδ T cell subsets—Nature's CAR‐T cells

Willcox, C. R., Mohammed, F., & Willcox, B. E. (2020) · Immunological Reviews · doi:10.1111/imr.12928 · Cited by 68

Absolute lymphocyte count proliferation kinetics after CAR T-cell infusion impact response and relapse

Faude, S., Wei, J. M., Muralidharan, K., Xu, X., Wertheim, G. B. W., Paessler, M. E., Bhoj, V. G., Grupp, S. A., Maude, S. L., Rheingold, S. R., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020004038 · Cited by 62

Immunotherapy in Pancreatic Adenocarcinoma: Beyond “Copy/Paste”

Hester, R., Mazur, P. K., & McAllister, F. M. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0900 · Cited by 67

Senescence in chronic wounds and potential targeted therapies

Wei, X., Li, M., Zheng, Z., Ma, J., Gao, Y., Chen, L., Peng, Y., Yu, S., & Yang, L. (2021) · Burns & Trauma · doi:10.1093/burnst/tkab045 · Cited by 70

Biomaterials to enhance adoptive cell therapy

Eckman, N., Nejatfard, A., Cavet, R., Grosskopf, A. K., & Appel, E. A. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00148-z · Cited by 66

State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019

Lemal, R., & Tournilhac, O. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0686-x · Cited by 67

Massively-Parallelized, Deterministic Mechanoporation for Intracellular Delivery

Dixit, H. G., Starr, R., Dundon, M. L., Pairs, P. I., Yang, X., Zhang, Y., Nampe, D. P., Ballas, C. B., Tsutsui, H., Forman, S. J., et al. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b03175 · Cited by 66

Enhancing Chimeric Antigen Receptor T Cell Anti-tumor Function through Advanced Media Design

Ghassemi, S., Martinez-Becerra, F. J., Master, А. M., Richman, S. A., Heo, D. S., Leferovich, J. M., Tu, V. Y., García‐Cañaveras, J. C., Ayari, A., Lu, Y., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.07.008 · Cited by 66

CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives

Mohty, M., Gauthier, J., Malard, F., Aljurf, M. D., Bazarbachi, A. A., Chabannon, C., Kharfan‐Dabaja, M. A., Savani, B. N., Huang, H., Kenderian, S. S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0615-5 · Cited by 65

Self-Assembled Nanomaterials for Enhanced Phototherapy of Cancer

Zhao, L., Xing, Y., Wang, R., Yu, F., & Yu, F. (2019) · ACS Applied Bio Materials · doi:10.1021/acsabm.9b00843 · Cited by 65

IL-23 and PSMA-targeted duo-CAR T cells in Prostate Cancer Eradication in a preclinical model

Wang, D., Shao, Y., Zhang, X., Lu, G., & Liu, B. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-019-02206-w · Cited by 64

Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials

Rochigneux, P., Chanez, B., de Rauglaudre, B., Mitry, E., Chabannon, C., & Gilabert, M. (2021) · Cancers · doi:10.3390/cancers13020271 · Cited by 68

CXCR5 CAR-T cells simultaneously target B cell non-Hodgkin’s lymphoma and tumor-supportive follicular T helper cells

Bunse, M., Pfeilschifter, J. M., Bluhm, J., Zschummel, M., Joedicke, J. J., Wirges, A., Stark, H., Kretschmer, V., Chmielewski, M. M., Uckert, W., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20488-3 · Cited by 64

Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models

Goto, S., Sakoda, Y., Adachi, K., Sekido, Y., Yano, S., Eto, M., & Tamada, K. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02853-3 · Cited by 64

Harnessing organs-on-a-chip to model tissue regeneration

Tavakol, D. N., Fleischer, S., & Vunjak‐Novakovic, G. (2021) · Cell stem cell · doi:10.1016/j.stem.2021.05.008 · Cited by 68

Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer

You, K. S., Yi, Y. W., Cho, J., Park, J., & Seong, Y. (2021) · Pharmaceuticals · doi:10.3390/ph14060589 · Cited by 64

Radiation enhances the efficacy of EGFR-targeted CAR-T cells against triple-negative breast cancer by activating NF-κB/Icam1 signaling

Zhou, M., Chen, M., Shi, B., Di, S., Sun, R., Jiang, H., & Li, Z. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.07.021 · Cited by 67

Inefficient exploitation of accessory receptors reduces the sensitivity of chimeric antigen receptors

Burton, J., Siller‐Farfán, J. A., Pettmann, J., Salzer, B., Kutuzov, M. A., van der Merwe, P. A., & Dushek, O. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2216352120 · Cited by 63

Materials for Cell Surface Engineering

Adebowale, K., Liao, R., Suja, V. C., Kapate, N., Lu, A., Gao, Y., & Mitragotri, S. (2023) · Advanced Materials · doi:10.1002/adma.202210059 · Cited by 64

Glycosylation Shapes the Efficacy and Safety of Diverse Protein, Gene and Cell Therapies

Rocamora, F., Peralta, A. G., Shin, S., Sorrentino, J., Wu, M. Y. M., Toth, E. A., Fuerst, T. R., & Lewis, N. E. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108206 · Cited by 67

Engineered T cell therapy for central nervous system injury

Gao, W., Kim, M. W., Dykstra, T., Du, S., Boskovic, P., Lichti, C. F., Ruiz-Cardozo, M. A., Gu, X., Shapira, T. W., Rustenhoven, J., et al. (2024) · Nature · doi:10.1038/s41586-024-07906-y · Cited by 71

Engineering synthetic suppressor T cells that execute locally targeted immunoprotective programs

Reddy, N. R., Maachi, H., Xiao, Y., Simic, M., Yu, W., Tonai, Y., Cabanillas, D. A., Serrano-Wu, E. M., Pauerstein, P. T., Tamaki, W., et al. (2024) · Science · doi:10.1126/science.adl4793 · Cited by 68

Will CAR T cell therapy have a role in AML? Promises and pitfalls

Cummins, K. D., & Gill, S. I. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.08.008 · Cited by 69

Adoptive cell therapy with tumor-specific Th9 cells induces viral mimicry to eliminate antigen-loss-variant tumor cells

Xue, G., Zheng, N., Fang, J., Jin, G., Li, X., Dotti, G., Yi, Q., & Lu, Y. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.09.011 · Cited by 64

Injectable and photocurable CAR-T cell formulation enhances the anti-tumor activity to melanoma in mice

Zhou, W., Lei, S., Liu, M., Li, D., Huang, Y., Hu, X., Yang, J., Li, J., Fu, M., Zhang, M., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121872 · Cited by 66

Chemically engineering cells for precision medicine

Wang, Y., Li, Z., Mo, F., Chen‐Mayfield, T., Saini, A., LaMere, A. M., & Hu, Q. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00142j · Cited by 62

The effect of low- and high-penetration light on localized cancer therapy

Costa, D. F. G., Mendes, L. P., & Torchilin, V. P. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.09.004 · Cited by 64

Hybridoma Technology: The Preferred Method for Monoclonal Antibody Generation for in vivo Applications

Zaroff, S., & Tan, G. (2019) · BioTechniques · doi:10.2144/btn-2019-0054 · Cited by 63

GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab

Kato, D., Yaguchi, T., Iwata, T., Katoh, Y., Morii, K., Tsubota, K., Takise, Y., Tamiya, M., Kamada, H., Akiba, H., et al. (2020) · eLife · doi:10.7554/elife.49392 · Cited by 64

GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy

Fernández, L., Fernández, A., Mirones, I., Escudero, A., Cardoso, L. C. D. A., Vela, M., Lanzarot, D., de Paz, R., Leivas, A., Gallardo, M., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02361 · Cited by 64

Multifunctional Dendrimer-Entrapped Gold Nanoparticles for Labeling and Tracking T Cells Via Dual-Modal Computed Tomography and Fluorescence Imaging

Chen, M., Betzer, O., Fan, Y., Gao, Y., Shen, M., Sadan, T., Popovtzer, R., & Shi, X. (2020) · Biomacromolecules · doi:10.1021/acs.biomac.0c00147 · Cited by 62

Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic

Zhang, X., Luo, M., Dastagir, S. R., Nixon, M. J., Khamhoung, A., Schmidt, A., Lee, A., Subbiah, N., McLaughlin, D. C., Moore, C. L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22898-3 · Cited by 64

Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity

Zhang, C., Röder, J., Scherer, A., Bodden, M., Serrahima, J. P., Bhatti, A., Waldmann, A., Müller, N., Oberoi, P., & Wels, W. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002980 · Cited by 54

Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook

Fan, Y., Xue, H., & Zheng, H. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s358082 · Cited by 65

Heterogeneity and transcriptome changes of human CD8+ T cells across nine decades of life

Lü, J., Ahmad, R., Nguyen, T. B. V., Cifello, J., Hemani, H., Li, J., Chen, J., Li, S., Wang, J., Achour, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32869-x · Cited by 64

A Nobel Prize‐worthy pursuit: cancer immunology and harnessing immunity to tumour neoantigens

Altmann, D. M. (2018) · Immunology · doi:10.1111/imm.13008 · Cited by 62

Preclinical Evaluation of Bispecific Adaptor Molecule Controlled Folate Receptor CAR-T Cell Therapy With Special Focus on Pediatric Malignancies

Lu, Y. J., Chu, H., Wheeler, L. W., Nelson, M., Westrick, E., Matthaei, J. F., Cardle, I. I., Johnson, A., Gustafson, J., Parker, N., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00151 · Cited by 61

Engineering Nano‐Therapeutics to Boost Adoptive Cell Therapy for Cancer Treatment

Zheng, C., Zhang, J., Chan, H. F., Hu, H., Lv, S., Na, N., Tao, Y., & Li, M. (2021) · Small Methods · doi:10.1002/smtd.202001191 · Cited by 61

No free rides: management of toxicities of novel immunotherapies in ALL, including financial

Jain, T., & Litzow, M. R. (2018) · Hematology · doi:10.1182/asheducation-2018.1.25 · Cited by 61

Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing

Lu, Y., Zheng, Z., Lowery, F. J., Gartner, J. J., Prickett, T. D., Robbins, P. F., & Rosenberg, S. A. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002595 · Cited by 63

Preclinical assessment of antigen-specific chimeric antigen receptor regulatory T cells for use in solid organ transplantation

Proïcs, E., David, M., Mojibian, M., Speck, M., Lounnas-Mourey, N., Govehovitch, A., Baghdadi, W., Desnouveaux, J., Bastian, H., Freschi, L., et al. (2022) · Gene Therapy · doi:10.1038/s41434-022-00358-x · Cited by 62

Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy

Kilgour, M. K., Bastin, D. J., Lee, S., Ardolino, M., McComb, S., & Visram, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1166038 · Cited by 66

Prospects and challenges of CAR-T cell therapy combined with ICIs

Lv, Y., Luo, X., Xie, Z., Qiu, J.-Y., Yang, J., Deng, Y., Long, R., Tang, G., Zhang, C., & Zuo, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1368732 · Cited by 62

Adoptive cell transfer therapy for hepatocellular carcinoma

Zhang, R., Zhang, Z., Liu, Z., Wei, D., Wu, X., Bian, H., & Chen, Z. (2019) · Frontiers of Medicine · doi:10.1007/s11684-019-0684-x · Cited by 62

Adenoviral vectors for in vivo delivery of CRISPR-Cas gene editors

Rice-Boucher, P. J., Cui, X., & Curiel, D. T. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.09.003 · Cited by 62

Novel targeted therapies of T cell lymphomas

Iżykowska, K., Rassek, K., Korsak, D., & Przybylski, G. K. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01006-w · Cited by 60

A multilayered blood vessel/tumor tissue chip to investigate T cell infiltration into solid tumor tissues

Lee, J., Kim, S.-E., Moon, D., & Doh, J. (2021) · Lab on a Chip · doi:10.1039/d1lc00182e · Cited by 59

Opportunities for Nitric Oxide in Potentiating Cancer Immunotherapy

Kim, J., & Thomas, S. N. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000500 · Cited by 60

Overcoming Cancer Resistance: Strategies and Modalities for Effective Treatment

Koirala, M., & DiPaola, M. (2024) · Biomedicines · doi:10.3390/biomedicines12081801 · Cited by 68

Characterization of clinical grade CD19 chimeric antigen receptor T cells produced using automated CliniMACS Prodigy system

Zhang, W., Jordan, K. R., Schulte, B., & Purev, E. (2018) · Drug Design, Development and Therapy · doi:10.2147/dddt.s175113 · Cited by 60

Beyond CAR T Cells: Other Cell-Based Immunotherapeutic Strategies Against Cancer

Patel, S., Burga, R. A., Powell, A. B., Chorvinsky, E. A., Hoq, N., McCormack, S., Pelt, S. N. V., Hanley, P. J., & Cruz, C. C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00196 · Cited by 60

Augmenting adaptive immunity: progress and challenges in the quantitative engineering and analysis of adaptive immune receptor repertoires

Brown, A. J., Snapkov, I., Akbar, R., Pavlović, M., Miho, E., Sandve, G. K., & Greiff, V. (2019) · Molecular Systems Design & Engineering · doi:10.1039/c9me00071b · Cited by 59

CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies

Achi, H. E., Dupont, É., Paul, S., & Khoury, J. D. (2020) · Cancers · doi:10.3390/cancers12113087 · Cited by 59

Cancer immunotherapy

Dhar, R., Seethy, A. A., Singh, S., Pethusamy, K., Srivastava, T. P., Talukdar, J., Rath, G. K., & Karmakar, S. (2021) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_1241_20 · Cited by 59

Nanobody‐Engineered Natural Killer Cell Conjugates for Solid Tumor Adoptive Immunotherapy

Gong, L., Li, Y., Cui, K., Chen, Y., Hong, H., Li, J., Li, D., Yin, Y., Wu, Z., & Huang, Z. (2021) · Small · doi:10.1002/smll.202103463 · Cited by 61

No free rides: management of toxicities of novel immunotherapies in ALL, including financial

Jain, T., & Litzow, M. R. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018020198 · Cited by 58

Next-generation cell therapies: the emerging role of CAR-NK cells

Başar, R., Daher, M., & Rezvani, K. (2020) · Hematology · doi:10.1182/hematology.2020002547 · Cited by 57

Fibroblasts orchestrate cellular crosstalk in the heart through the ECM

Bowers, S., Meng, Q., & Molkentin, J. D. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00043-7 · Cited by 61

Metformin-containing hydrogel scaffold to augment CAR-T therapy against post-surgical solid tumors

Chao, Y., Wei, T., Li, Q., Liu, B., Hao, Y., Chen, M., Wu, Y., Song, F., Chen, Q., & Liu, Z. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122052 · Cited by 60

Challenges of Anti-Mesothelin CAR-T-Cell Therapy

Zhai, X., Mao, L., Wu, M., Liu, J., & Yu, S. (2023) · Cancers · doi:10.3390/cancers15051357 · Cited by 59

Current trends of clinical trials involving CRISPR/Cas systems

Zhang, S., Wang, Y., Mao, D., Wang, Y., Zhang, H., Pan, Y., Wang, Y., Teng, S., & Huang, P. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1292452 · Cited by 62

Mesoporous Silica Nanoparticles as an Ideal Platform for Cancer Immunotherapy: Recent Advances and Future Directions.

Godakhindi, V., Tarannum, M., Dam, S. K., & Vivero-Escoto, J. L. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400323 · Cited by 65

T Cell-Redirecting Strategies to ‘STAb’ Tumors: Beyond CARs and Bispecific Antibodies

Blanco, B., Compte, M., Lykkemark, S., Sanz, L., & Álvarez‐Vallina, L. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.01.008 · Cited by 59

Immunotherapy for pancreatic cancer

Yoon, J. H., Jung, Y.-J., & Moon, S. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i13.2969 · Cited by 58

Harnessing Antitumor CD4+ T Cells for Cancer Immunotherapy

Khelil, M. B., Godet, Y., Abdeljaoued, S., Borg, C., Adotévi, O., & Loyon, R. (2022) · Cancers · doi:10.3390/cancers14010260 · Cited by 63

De novo-designed transmembrane domains tune engineered receptor functions

Elazar, A., Chandler, N. J., Davey, A. S., Weinstein, J. J., Nguyen, J. V., Trenker, R., Cross, R. S., Jenkins, M. R., Call, M. J., Call, M. E., et al. (2022) · eLife · doi:10.7554/elife.75660 · Cited by 58

Optimizing the manufacturing and antitumour response of CAR T therapy

Liu, Y., Sperling, A. S., Smith, E. L., & Mooney, D. J. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00031-x · Cited by 60

Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors

Zhong, W., Xiao, Z., Qin, Z., Yang, J., Wen, Y., Yu, Z., Li, Y., Sheppard, N. C., Fuchs, S. Y., Xu, X., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-2220 · Cited by 63

Chimeric antigen receptor engineered natural killer cells for cancer therapy

Zhang, Y., Zhou, W., Yang, J., Yang, J., & Wang, W. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00431-0 · Cited by 58

Immunoengineering can overcome the glycocalyx armour of cancer cells

Park, S., Colville, M. J., Paek, J. H., Shurer, C. R., Singh, A. L., Secor, E. J., Sailer, C. J., Huang, L., Kuo, J. C., Goudge, M. C., et al. (2024) · Nature Materials · doi:10.1038/s41563-024-01808-0 · Cited by 58

A biodegradable thermosensitive hydrogel vaccine for cancer immunotherapy

Yang, F., Shi, K., Jia, Y., Hao, Y., Peng, J., Yuan, L., Chen, Y., Pan, M., & Qian, Z. (2020) · Applied Materials Today · doi:10.1016/j.apmt.2020.100608 · Cited by 57

Mechanical Immunoengineering of T cells for Therapeutic Applications

Lei, K., Kurum, A., & Tang, L. (2020) · Accounts of Chemical Research · doi:10.1021/acs.accounts.0c00486 · Cited by 59

Immunostimulatory silica nanoparticle boosts innate immunity in brain tumors

Bielecki, P. A., Lorkowski, M. E., Becicka, W. M., Atukorale, P. U., Moon, T. J., Zhang, Y., Wiese, M. L., Covarrubias, G., Ravichandran, S., & Karathanasis, E. (2020) · Nanoscale Horizons · doi:10.1039/d0nh00446d · Cited by 58

Delivery Techniques for Enhancing CAR T Cell Therapy against Solid Tumors

Fu, R., Li, H., Li, R., McGrath, K. V., Dotti, G., & Gu, Z. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202009489 · Cited by 58

Approaches and materials for endocytosis-independent intracellular delivery of proteins

Chen, N., He, Y., Zang, M., Zhang, Y., Lü, H., Zhao, Q., Wang, S., & Gao, Y. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121567 · Cited by 59

Application of lipid-based nanoparticles in cancer immunotherapy

Zhang, Z., Yao, S., Hu, Y., Zhao, X. B., & Lee, R. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.967505 · Cited by 58

Customized Multifunctional Peptide Hydrogel Scaffolds for CAR-T-Cell Rapid Proliferation and Solid Tumor Immunotherapy

Jie, J., Mao, D., Cao, J., Feng, P.-F., & Yang, P. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c10727 · Cited by 59

Individual HLA heterogeneity and its implications for cellular immune evasion in cancer and beyond

Pagliuca, S., Gurnari, C., Rubio, M., Visconte, V., & Lenz, T. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.944872 · Cited by 56

Cytokine conjugation to enhance T cell therapy

Liu, Y., Adu‐Berchie, K., Brockman, J. M., Pezone, M. J., Zhang, D. K. Y., Zhou, J., Pyrdol, J. W., Wang, H., Wucherpfennig, K. W., & Mooney, D. J. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2213222120 · Cited by 57

The role of MSCs and CAR-MSCs in cellular immunotherapy

Yan, L., Li, J., & Zhang, C. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01191-4 · Cited by 59

Research progress on the immune microenvironment and immunotherapy in gastric cancer

Mou, P., Ge, Q., Sheng, R., Zhu, T.-F., Liu, Y., & Ding, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1291117 · Cited by 58

Cell Fate Reprogramming in the Era of Cancer Immunotherapy

Zimmermannova, O., Caiado, I., Ferreira, A. G., & Pereira, C.-F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.714822 · Cited by 56

Linking genome variants to disease: scalable approaches to test the functional impact of human mutations

Findlay, G. M. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab219 · Cited by 58

The role of tumor microenvironment and exosomes in dormancy and relapse

Attaran, S., & Bissell, M. J. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.09.008 · Cited by 57

CAR T-Cell therapy for the management of mantle cell lymphoma

Huang, Z., Chavda, V. P., Bezbaruah, R., Dhamne, H., Yang, D., & Zhao, H.-B. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01755-5 · Cited by 64

Cancer organoids: A platform in basic and translational research

Ma, X., Wang, Q. L., Li, G., Li, H., Xu, S., & Pang, D. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.02.052 · Cited by 62

A Review on the Stability Challenges of Advanced Biologic Therapeutics

Sarvepalli, S., Pasika, S. R., Verma, V., Thumma, A., Bolla, S., Nukala, P. K., Butreddy, A., & Bolla, P. K. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17050550 · Cited by 63

Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors

Reul, J., Frisch, J., Engeland, C. E., Thalheimer, F. B., Hartmann, J., Ungerechts, G., & Buchholz, C. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00052 · Cited by 56

Systems immunology: Integrating multi-omics data to infer regulatory networks and hidden drivers of immunity

Yu, J., Peng, J., & Chi, H. (2019) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2019.03.003 · Cited by 61

Tuning the size, shape and structure of RNA nanoparticles for favorable cancer targeting and immunostimulation

Guo, S., Xu, C., Yin, H., Hill, J. L., Pi, F., & Guo, P. (2019) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1582 · Cited by 57

Therapeutic applications of the cancer immunoediting hypothesis

Desai, R. R., Coxon, A. T., & Dunn, G. P. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.002 · Cited by 59

Strategies for Dodging the Obstacles in CAR T Cell Therapy

Kozani, P. S., Kozani, P. S., Rahbarizadeh, F., & Nikkhoi, S. K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.627549 · Cited by 57

A β-1,3/1,6-glucan from Durvillaea Antarctica inhibits tumor progression in vivo as an immune stimulator

Su, F., Song, Q., Zhang, C., Xu, X., Li, M., Yao, D., Wu, L., Qu, X., Guan, H., Yu, G., et al. (2019) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2019.114993 · Cited by 57

Engineering CAR T Cells to Target the HIV Reservoir

Mu, W., Carrillo, M. A., & Kitchen, S. G. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00410 · Cited by 55

Nanoparticle-mediated synergistic chemoimmunotherapy for tailoring cancer therapy: recent advances and perspectives

Bagherifar, R., Kiaie, S. H., Hatami, Z., Ahmadi, A., Sadeghnejad, A., Baradaran, B., Jafari, R., & Javadzadeh, Y. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00861-0 · Cited by 56

Trial Watch: Adoptive cell transfer for oncological indications

Aranda, F., Buqué, A., Bloy, N., Castoldi, F., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Fucikova, J. P., Galon, J., Špíšek, R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1046673 · Cited by 33

Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street

Barrett, D. M., Grupp, S. A., & June, C. H. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500751 · Cited by 182

Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer

Lundh, S. M., Jung, I.-Y., Dimitri, A. J., Vora, A., Melenhorst, J. J., Jadlowsky, J. K., & Fraietta, J. A. (2020) · Clinical and Experimental Medicine · doi:10.1007/s10238-020-00628-1 · Cited by 10

Improving cell reinfusion to enhance the efficacy of chimeric antigen receptor T-cell therapy and alleviate complications

Han, Z., Ma, X., & Ma, G. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28098 · Cited by 3

Abstract KN01: Updates on engineered T cells as cancer therapies

June, C. H. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-15-kn01